DECISION DIAGNOSTICS CORP.

QUARTERLY REPORT FOR OTC PINK

SUPPLEMENTAL DISCLOSURES

Quarterly Report for Period Ended

June 30, 2017

Trading Symbol: **DECN**
CUSIP Number: **243443 108**

Decision Diagnostics Corp.

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

DECISION DIAGNOSTICS CORP. (11/25/2011-present)
INSTACARE CORP. (through 11/25/2011)

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 2660 TOWNSGATE ROAD
Address 2: SUITE 300
Address 3: WESTLAKE VILLAGE, CA 91361
Phone: 805-446-1973
Email: info@decisiondiagnostics.com
Website(s): www.decisiondiagnostics.com

IR Contact N/A

3) Security Information

Trading Symbol: DECN
Exact title and class of securities outstanding: COMMON
CUSIP: **243443 108**
Par or Stated Value: $0.001
Total shares authorized: 494,995,000 as of: 06/30/2017
Total shares outstanding: 92,077,522 as of: 06/30/2017

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 3,738,500 as of: 06/30/2017
Total shares outstanding: N/A as of: 06/30/2017

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "B"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 2,500 as of: 06/30/2017
Total shares outstanding: 1,000 as of: 06/30/2017

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "C"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 10,000 as of: 06/30/2017
Total shares outstanding: 6,187 as of: 06/30/2017

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "D"*
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 1,250 as of: 06/30/2017
Total shares outstanding: NONE as of: 06/30/2017

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "E"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 1,250,000 as of: 06/30/2017
Total shares outstanding: 977,540 as of: 06/30/2017

Transfer Agent
Name: ACTION STOCK TRANSFER CORP.
Address 1: 2469 E. FORT UNION BLVD.
Address 2: SUITE 214
Address 3: SALT LAKE CITY, UT 84121
Phone: 801-274-1088
Is the Transfer Agent registered under the Exchange Act?* Yes: XX No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

* In April 2015 the company completed voluntary disclosure, periodic financial, and management's discussion and analysis filings (postings) with OTCMarkets, for the purposes of becoming a current voluntary filer. The company's filings were reviewed and the company was granted current filer status with OTCMarkets on April 21, 2015 and again on August 22, 2016.

** On May 4, 2017 the company received direct communication from OTCMarkets concerning a new policy to be implemented by OTCMarkets whereby OTC Pink Alternative filers could become eligible for Tier uplist to the OTCMarkets OTCQB tier. The company confirmed this with OTCMarkets and filed the uplist application. In late June 2017 the company was told by OTCMarkets that new Tier rules would require the company to have their balance sheet audited for FY2016, and then each fiscal year thereafter. The company has received engagement letters from two accounting firms, and expects to receive an engagement letter from a third firm during the month of August 2017 and the company's Board of Directors will determine which of the three firms will be engaged for this work during 3Q 2017.

*** In February 2016 the company completed re-designations for its Preferred Series "D" stock. Of note in these re-designations, the company increased the number of Preferred "D" shares authorized from 500 to 1,250 and changed the holding period prior for any contemplated conversions of Preferred "D" shares into common stock shares from twelve (12) months to thirty-six (36) months. These re-designations are reflected in filings for the periods ending March 31, 2017 and June 30, 2017. To date no shares of Preferred Series "D" stock have been issued, although Subscriptions have been accepted.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

1:14 reverse stock split of $0.001 par value common stock effective 11/25/2011
1:25 reverse stock split followed immediately by a 1:25 forward stock split effective August 4, 2016

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

COMMON STOCK

Date	Description	Change in Shares	Running Total
12/1/2011	1 for 14 Reverse Split	8,461,032	8,461,032
12/19/2011	New Issuance-Kimberly Binder	75	8,461,107
12/19/2011	New Issuance-Patrick DiParini	200	8,461,307
12/30/2011	10% Stock Dividend	846,669	9,307,976
1/3/2012	DTC Rounding shares	(42)	9,307,934
1/4/2012	New Issuance-Positive Revolution Inc-S-8	100,000	9,407,934
1/11/2012	Converted to Common-Alpha Credit	294,000	9,701,934
1/18/2012	New Issuance-Debt Conv. Andrew Edenbaum	53,354	9,755,288
1/23/2012	DTC Rounding shares	25	9,755,313
3/5/2012	New Issuance-JFS Investments Inc	60,000	9,815,313
3/5/2012	New Issuance-Garden State Securities	60,000	9,875,313
3/5/2012	New Issuance-Excell Advisors	30,000	9,905,313
3/5/2012	Return to Treasury-Positive Revolution	(100,000)	9,805,313
3/5/2012	New Issuance-TPC Holdings Group-ESOP-06	300,000	10,105,313
3/5/2012	New Issuance-Cadence Consulting-ESOP-06	50,000	10,155,313
3/30/2012	New Issuance-Alpha Credit Resources	238	10,155,551
6/27/2012	New Issuance-Rocio C Carazas-ESOP-06	375,000	10,530,551
6/27/2012	New Issuance-Marjolein Imfeld-ESOP-06	375,000	10,905,551
9/26/2012	Converted to Common-Centurion	172,200	11,077,751
10/9/2012	New Issuance-Aubyn Inc-ESOP-06	400,000	11,477,751
11/8/2012	Return to Treasury-Aubyn Inc-ESOP-06	(200,000)	11,277,751
11/8/2012	New Issuance-Mayer & Assoc. Esop-04	650,000	11,927,751
11/8/2012	New Issuance-Mayer & Associates	200,000	12,127,751
11/8/2012	New Issuance-Curing Capital Inc	400,000	12,527,751
11/13/2012	Converted to Common-Centurion	182,000	12,709,751
11/13/2012	New Issuance-Econ Corporate Services	50,000	12,759,751

11/13/2012	New Issuance-Call Van Zant-ESOP-06	100,000	12,859,751
11/13/2012	New Issuance-Darren Bankstead-ESOP-06	50,000	12,909,751
11/13/2012	New Issuance-Axiom Financial Inc	200,000	13,109,751
12/21/2012	Cancellation-Mayer & Associates LLC	(200,000)	12,909,751
12/21/2012	New Issuance-Mayer & Associates LLC	1,000,000	13,909,751
1/7/2013	New Issuance-Mayer & Associates LLC	50,000	13,959,751
1/7/2013	Converted to Common-Apex Clearing	210,000	14,169,751
1/7/2013	Converted to Common-Apex Clearing	236,600	14,406,351
2/15/2013	New Issuance-TPC Holdings Group-ESOP	1,325,000	15,731,351
2/15/2013	New Issuance-Envisionte LLC-ESOP	700,000	16,431,351
2/15/2013	New Issuance-Bridgeview Capital ESOP	700,000	17,131,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	275,000	17,406,351
2/15/2013	New Issuance-AAC Group LLC ESOP	600,000	18,006,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	150,000	18,156,351
2/15/2013	New Issuance-St Andrews Inc	1,000,000	19,156,351
2/15/2013	New Issuance-Alan Binder ESOP	100,000	19,256,351
2/15/2013	New Issuance-Dale Richter ESOP	100,000	19,356,351
2/15/2013	New Issuance-Kimberly Binder ESOP	50,000	19,406,351
2/15/2013	New Issuance-Maria Luz Johnson-ESOP	25,000	19,431,351
2/18/2013	Converted to Common-Apex Clearing	324,800	19,756,151
2/22/2013	New Issuance-Robert Herskowitz ESOP	500,000	20,256,151
2/22/2013	New Issuance-Jeff Whitelaw	125,000	20,381,151
2/22/2013	New Issuance-Brent England	75,000	20,456,151
5/9/2013	Converted to Common-Apex Clearing	868,000	21,324,151
5/10/2013	Cancellation-Robert Herskowitz ESOP	(500,000)	20,824,151
5/10/2013	Cancellation-St. Andrews	(1,000,000)	19,824,151
5/10/2013	New Issuance-Chase Financing Inc ESOP	350,000	20,174,151
5/10/2013	New Issuance-Mayer & Associates LLC ESOP	1,000,000	21,174,151
8/7/2013	New Issuance-St Andrews Inc ESOP	500,000	21,674,151
8/15/2013	New Issuance-Robert Herskowitz ESOP	25,000	21,699,151
8/27/2013	Cancellation-Curring Capital	(200,000)	21,499,151
8/27/2013	Cancellation-ACC Group ESOP	(600,000)	20,899,151
8/27/2013	New Issuance-Benjamin Mayer ESOP	950,000	21,849,151
9/20/2013	New Issuance-SLCC Partners LLC	1,000,000	22,849,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	500,000	23,349,151
9/20/2013	New Issuance-Thomas Hanson-ESOP	250,000	23,599,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	250,000	23,849,151
10/2/2013	New Issuance-Joanne Broeders-ESOP	235,300	24,084,451
10/2/2013	Cancellation-Alan Binder ESOP	(100,000)	23,984,451
10/2/2013	New Issuance-Kimberly Binder	100,000	24,084,451
10/2/2013	Converted to Common-COR Clearing	1,078,000	25,162,451
10/28/2013	Converted to Common-Michael Belcher	350,000	25,512,451
10/28/2013	New Issuance	2,798,728	28,311,179
10/30/2013	New Issuance-Benjamin Mayer ESOP	100,000	28,411,179
10/30/2013	New Issuance-Benjamin Mayer	300,000	28,711,179
10/30/2013	New Issuance	166,365	28,877,544
11/11/2013	Conversion-Centurion Credit	980,000	29,857,544
11/11/2013	New Issuance-Benjamin Mayer ESOP	500,000	30,357,544
11/11/2013	New Issuance	125,000	30,482,544
12/4/2013	Conversion-Centurion Credit	1,220,800	31,703,344
12/23/2013	New Issuance-Mark Herskowitz ESOP	175,000	31,878,344
12/23/2013	New Issuance-Benjamin Mayer ESOP	600,000	32,478,344

12/23/2013	New Issuance	1,200,548	33,678,892
1/2/2014	New Issuance	2,709,678	36,388,570
1/15/2014	New Issuance	748,720	37,137,290
1/15/2014	New Issuance	267,105	37,404,395
2/18/2014	Conversion-Alpha Credit	611,940	38,016,335
2/18/2014	Conversion-Michael Belcher	350,000	38,366,335
2/19/2014	Conversion-Mayer & Associates	798,000	39,164,335
3/28/2014	Conversion-Alpha Credit	523,740	39,688,075
3/28/2014	New Issuance	400,000	40,088,075
6/3/2014	Conversion-Alpha Credit	499,996	40,588,071
6/4/2014	Conversion-Mayer & Associates	1,115,660	41,703,731
8/14/2014	Conversion-Alpha Credit	245,000	41,948,731
8/15/2014	Conversion-Mayer & Associates	550,000	42,498,731
9/9/2014	Conversion-Mayer & Associates	775,000	43,273,731
10/28/2014	Conversion	675,010	43,948,741
1/21/2015	New Issuance	1,875,000	45,823,741
1/28/2015	New Issuance	850,000	46,673,741
2/23/2015	Conversion-Alpha Credit	705,124	47,378,865
5/11/2015	New Issuance-Momona Capital	235,000	47,613,865
5/12/2015	Conversion-Mayer & Associates	950,040	48,563,905
5/12/2015	New Issuance-Robert Herskowiz	950,000	49,513,905
5/21/2015	New Issuance-Momona Capital	235,000	49,748,905
6/1/2015	New Issuance-Chase Financing 401K	533,334	50,282,239
6/8/2015	New Issuance-Momona Capital	437,250	50,719,489
6/8/2015	New Issuance-St Andrews	350,000	51,069,489
6/29/2015	New Issuance-Alpha Capital Anstalt	384,537	51,454,026
7/27/2015	New Issuance-Alpha Capital Anstalt	387,907	51,841,933
8/24/2015	New Issuance-Alpha Capital Anstalt	313,022	52,154,955
9/16/2015	Conversion-Mayer & Associates	1,890,000	54,044,955
9/16/2015	Conversion-Robert Herskowitz	1,400,000	55,444,955
10/27/2015	New Issuance-Alpha Capital Anstalt	479,489	55,924,444
12/2/2015	New Issuance-Alpha Capital Anstalt	950,545	56,874,989
12/15/2015	New Issuance-Alpha Capital Anstalt	950,545	57,825,534
12/21/2015	New Issuance-Alpha Capital Anstalt	956,950	58,782,484
2/2/2016	New Issuance-Alpha Capital Anstalt	970,980	59,753,464
2/17/2016	New Issuance-Alpha Capital Anstalt	1,614,248	61,367,712
2/25/2016	New Issuance-Robert Herskowiz	750,000	62,117,712
3/21/2016	New Issuance-Paradigm Capital Holdings	1,400,000	63,517,712
3/21/2016	New Issuance-Robert Herskowitz	200,000	63,717,712
3/29/2016	New Issuance-Alpha Capital Anstalt	404,630	64,122,342
3/29/2016	New Issuance-James J Loures	500,000	64,622,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	64,902,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	65,182,342
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	140,000	65,322,342
4/13/2016	New Issuance-Chase Financial	148,160	65,470,502
4/13/2016	New Issuance-Mark Herskowittz	185,195	65,655,697
4/13/2016	New Issuance-Andrew Schoenzeit	37,040	65,692,737
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	431,376	66,124,113
4/26/2016	New Issuance-LICGO Partners	1,837,500	67,961,613
4/26/2016	Conversion-Mayer & Associates	200,200	68,161,813
5/2/2016	New Issuance-Robert Herskowitz	472,106	68,633,919
5/5/2016	New Issuance-Alpha Capital Anstalt	998,099	69,632,018

5/17/2016	New Issuance-Alpha Capital Anstalt	422,669	70,054,687
5/17/2016	New Issuance-Navesink	625,000	70,679,687
5/18/2016	New Issuance-LICGO Partners	525,000	71,204,687
5/18/2016	Conversion-Mayer & Associates	220,000	71,424,687
6/1/2016	New Issuance-Alpha Capital Anstalt	814,314	72,239,001
6/6/2016	New Issuance-Mark Herskowitz	1,000,000	73,239,001
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	74,289,001
6/6/2016	New Issuance-Robert Herskowitz	280,000	74,569,001
6/6/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	74,639,001
6/8/2016	New Issuance-Alpha Capital Anstalt	484,148	75,123,149
6/27/2016	New Issuance-Navesink	625,000	75,748,149
7/18/2016	New Issuance-TPC Holdings Group	150,000	75,998,149
7/21/2016	New Issuance-Robert Herskowitz	690,000	76,688,149
7/21/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	76,758,149
7/21/2016	New Issuance-Chase Financial	945,000	77,703,149
8/2/2016	New Issuance-Navesink	625,000	78,328,149
8/29/2016	New Issuance-Alpha Capital Anstalt	954,925	79,283,074
9/7/2016	New Issuance-Chase Financial	945,000	80,228,074
9/19/2016	New Issuance-Alpha Capital Anstalt	521,784	80,749,858
9/19/2016	New Issuance-Mark Herskowitz	805,147	81,555,005
9/19/2016	New Issuance-Marc Berger	400,000	81,955,005
11/21/2016	New Issuance-Alpha Capital Anstalt	957,485	82,922,490
12/6/2016	New Issuance-Alpha Capital Anstalt	962,118	83,884,608
12/12/2016	New Issuance-LICGO Partners	755,300	84,639,908
1/9/2017	New Issuance-Alpha Capital Anstalt	971,074	85,610,982
1/9/2017	New Issuance-Mark Herskowitz	400,000	86,010,982
3/1/2017	New Issuance-Alpha Capital Anstalt	989,425	87,000,407
3/3/2017	New Issuance-Chase Financial	1,400,000	88,400,407
3/3/2017	New Issuance-Robert Herskowitz	560,000	88,960,407
3/3/2017	New Issuance-R Herskowitz 2011 Irrv. TR	140,000	89,100,407
3/10/2017	Issuance-Mark Herskowitz	400,000	89,500,407
3/21/2017	New Issuance-Alpha Capital Anstalt	355,803	89,856,210
4/19/2017	New Issuance-Paradigm Capital Holdings	400,000	90,256,210
5/10/2017	New Issuance-Navesink	625,000	90,881,210
5/17/2017	New Issuance-OmniVance Advisors LLC	100,000	90,981,210
6/19/2017	New Issuance-Alpha Capital Anstalt	1,096,312	92,077,522

PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/011	New Issuance-Centurion Credit Resources	1,000	1,000

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
1/4/2012	New Issuance-Michael Belcher	1,250	1,250
8/27/2013	New Issuance-Lathrop Gage LLC	1,500	2,750
10/28/2013	Conversion-Michael Belcher	(70)	2,680
2/18/2014	Conversion-Michael Belcher	(70)	2,610
12/30/2015	New Issuance-Navesink Device Initiatives	1,475	4,085
3/21/2016	New Issuance-Paradigm Capital	800	4,885
4/26/2016	New Issuance-LICGO Partners	1,050	5,935

4/26/2016	New Issuance-Paradigm Capital	325	6,260
5/17/2016	Conversion-Navesink Device	(125)	6,135
5/18/2016	New Issuance-LICGO Partners	300	6,435
5/18/2016	New Issuance-Paradigm Capital	50	6,485
6/27/2016	Conversion-Navesink Device	(125)	6,360
8/2/2016	Conversion-Navesink Device	(125)	6,235
4/19/2017	Conversion-Paradigm Capital	(80)	6,155
4/19/2017	New Issuance-LICGO Partners	157	6,312
5/10/2017	Conversion-Navesink Device	(125)	6,187

PREFERRED E STOCK

Date	Description	Change in Shares	Running Total
5/17/2011	New Issuance-Centurion Credit	135,000	1,095,300
1/11/2012	Converted to Common	(21,000)	1,074,300
3/30/2012	New Issuance-Alpha Credit Resources	124,700	1,199,000
9/26/2012	Converted to Common	(12,300)	1,186,700
11/13/2012	Converted to Common	(13,000)	1,173,700
1/7/2013	Converted to Common	(15,000)	1,158,700
1/7/2013	Converted to Common	(16,900)	1,141,800
2/18/2013	Converted to Common	(23,200)	1,118,600
5/9/2013	Converted to Common	(62,000)	1,056,600
10/2/2013	Converted to Common	(77,000)	979,600
11/11/2013	Conversion-Centurion Credit	(70,000)	909,600
12/4/2013	Conversion-Centurion Credit	(87,200)	822,400
1/15/2014	Conversion-Alpha Credit	(53,480)	768,920
2/18/2014	New Issuance-Mayer & Associates	125,000	893,920
2/18/2014	Conversion-Alpha Credit	(43,710)	850,210
2/19/2014	Conversion-Mayer & Associates	(57,000)	793,210
3/28/2014	Conversion-Alpha Credit	(37,400)	755,810
6/3/2014	Conversion-Alpha Credit	(35,714)	720,096
6/4/2014	Conversion-Mayer & Associates	(79,690)	640,406
8/14/2014	Conversion-Alpha Credit	(17,500)	622,906
8/15/2014	Conversion-Mayer & Associates	(39,285)	583,621
9/9/2014	Conversion-Mayer & Associates	(55,357)	528,264
10/28/2014	Conversion-Mayer & Associates	(30,358)	497,906
1/21/2015	New Issuance-Robert Herskowitz	100,000	597,906
1/21/2015	New Issuance-Mayer & Associates	135,000	732,906
1/21/2015	New Issuance-Alpha Credit Resources	67,860	800,766
2/23/2015	New Issuance-Alpha Credit Resources	(50,366)	750,400
5/12/2015	Conversion-Mayer & Associates	(67,860)	682,540
5/12/2015	New Issuance-Robert Herskowitz	30,000	712,540
7/27/2015	New Issuance-Chase Financing	75,000	787,540
9/16/2015	Conversion-Mayer & Associates	(135,000)	652,540
9/16/2015	Conversion-Robert Herskowitz	(100,000)	552,540
9/16/2015	New Issuance-Chase Financing	135,000	687,540
2/25/2016	New Issuance-Robert Herskowitz	100,000	787,540
3/21/2016	New Issuance-Mayer & Associates	14,300	801,840
4/26/2016	Conversion-Mayer & Associates	(14,300)	787,540
4/26/2016	New Issuance-Mayer & Associates	14,300	787,540
5/18/2016	Conversion-Mayer & Associates	(14,300)	773,240
6/6/2016	New Issuance-Mark Herskowitz 401K Trust	100,000	873,240
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	35,000	908,240

6/6/2016	New Issuance-Chase Financing	100,000	1,008,240
6/6/2016	Conversion-Chase Financing Inc Profit Sh.	(75,000)	933,240
7/21/2016	Conversion-Chase Financing Inc	(67,500)	865,740
7/21/2016	Conversion-Robert Herskowitz	(30,000)	835,740
9/7/2016	Conversion-Chase Financing Inc	(67,500)	768,240
9/19/2016	New Issuance-Chase Financing Inc Profit Sh.	75,000	843,240
1/9/2017	New Issuance-Chase Financing Inc Profit	105,000	948.240
3/3/2017	Cancellation	(105,000)	843,240
3/3/2017	New Issuance-Chase Financing	50,000	893.240
3/3/2017	New Issuance-Chase Financing Inc Profit	70,000	963,240
3/3/2017	Conversion-Chase Financing	(100,000)	863,240
5/17/2017	New Issuance-Chase Financing	100,000	963,240

A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See above

5) Financial Statements

SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE STATEMENT

6) Describe the Issuer's Business, Products and Services

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of the Genstrip 50 (discontinued in November 2016) and GenUltimate! glucose test strips, both Class II medical devices for at-home use for the measurement of glucose. A new product, GenSure! is complete and on August 18, 2017 will enter the initial manufacturing phase under company oversight with the company's Korean contract manufacturer. The company's GenChoice! glucose test strip, is now in advanced development, a prelude to the September 2017 clinical trials testing. The GenSure! product has completed its clinical trials, and is currently in registration and we are seeking "CE" marking in the EU. GenSure! will be launched overseas in September 2017. We have identified International distributors for this product.

When our GenChoice! product enters clinical trials during the month of September 2017, these trials will be run in Pennsylvania and California. At the conclusion of the clinical trials, the GenChoice! product will be registered in the EU and with the U.S. FDA through a 510K pre-market clearance. The company has previously contracted with two expert organizations, one who will manage the clinical trials (the IRB) and another who will write the 510K document and prosecute this document at the direction of the company.

Another new product nearing completion is the company's GenPrecis! system product. GenPrecis will consist of the GenPrecis! Precise glucometer, and the GenPrecis! test strip. The company will sell the GenPrecis! products in the USA and in all International markets. The GenPrecis! test strip will also serve as an alternative strip that will also run on an existing legacy meter. The GenPrecis! product is designed to be the most precise meter in the clinical markets, and is expected to set new standards for precision. Initial testing show that the GenPrecis! product will operate at a precision level of (better than) +/- 10 mg/dl in repeated samplings 97% of the time, while current published standards call for precision levels +/- 15 mg/dl in repeated samplings 95% of the time.

The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products in a similar but somewhat streamlined process, to the regulation of prescription medicine. The regulatory standard used for the Genstrip 50 was the 510k pre-market and post-market processes. The same process will be used for the GenChoice! test strip beginning with the pre-market approval with the FDA. Previous to this change in business model, from 2005 and until 2013, the company contracted with independent pharmacies for use of their prescription drug distribution licenses. At that time the company made market and sold brand

name over the counter pharmaceutical items with a concentration in legacy diabetic test strips. The brand name products we distributed, for the most part, did not require a doctor's prescription for anything other than insurance benefit compliance. Our previous business model worked well in the previous regulated environment, although the financial benefits were stressed by major changes made to the Federal Medicare plan that have led to substantially lower rates of reimbursement and ultimately an unprofitable business model.

Our subsidiaries, Pharma Tech Solutions, Inc., PDA Services, Inc. and PharmaTech Sensor Development Corp. operate in several healthcare products channels. In addition, our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! and our in development GenSure! and GenChoice! products. Our newest subsidiary Pharmatech Sensor Development Corp. manages our investment in specialty manufacturing machinery and testing laboratories, as well as an inventory credit line to finance inventory purchases of our Genstrip 50 and GenUltimate! products and soon to be our GenSure! and GenChoice! Products. This credit line was expanded in August 2017 for the management of our GenChoice! product later in 2017 and into 2018. The company has discontinued its GenStrip 50 product and ended the selling of the last of the inventory in November 2016.

As summarized above, in March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a new product which the company named GenPrecis!. This product, expected to be completed early in 4Q 2017, will represent a major improvement in diabetic glucose monitoring. The GenPrecis! system will be the first of its kind (better than) +/- 10% system. Current ISO (2015) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard, whereby the meter and strip must be within +/- 15% in repeated samplings 95% of the time. GenUltimate!, GenSure!, and GenChoice! are +/- 15% test strips, but in each case 97+% of the time in repeated samplings. GenPrecis! is designed to meet the written standards of the ISO and FDA at +/- 10%, in repeated samplings 97% of the time – effectively setting a new standard. The company has been funding the development of this system product, and a test strip only derivative version. The system product will be ready for in-house testing in September 2017 and will be registered for International sale in November 2017. However, the natural market for this product will be the U.S, and Canada where precision standards are higher for new products. The company expects to file for FDA pre-market approval right after New Year 2018.

From time to time, when economic conditions warrant and given market conditions, we distribute other brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound care and post-surgery medical products, although these healthcare channels have also undergone two major market changes and disruptions since July 2013 and we have determined that we will maintain our contacts but will refrain from competing. Our main product was the Genstrip 50 and currently the GenUltimate! both of improved performance and design improvements and a rebranding and redevelopment of the original Shasta Technologies Genstrip. Both of these glucose test strips are of our manufacture. We maintain FDA registered contract manufacturers in Pennsylvania and South Korea. The original GenStrip was cleared for market by the FDA on November 30, 2012. By virtue of our written agreements with Shasta in 2011, we were granted an irrevocable license to prosecute their 510k application with the U.S. FDA, and we succeeded. We introduced the original Genstrip in March 2013. We then acquired Genstrip from Shasta Technologies LLC on March 20, 2014 and in late June 2014 we made the first branding changes. We began work on the GenUltimate! product in July 2015 and introduced this improved test strip (vs. our GenStrip) in April 2016. The original Shasta Genstrip and our Genstrip 50 have been discontinued.

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, effectively ending Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry. It is confusing to consider what Shasta could have possibly been thinking. The company's acquisition of Genstrip (now GenUltimate!) was fortuitous in its timing given the finality and outcome of Shasta Technologies' troubles with the FDA. The GenSure!, GenChoice! and GenPrecis! products are the exclusive IP, technical and design work of the company's PharmaTech Solutions, Inc. subsidiary.

The worldwide market for at-home blood glucose testing is an estimated $13.0 billion, inclusive of the 2013 and 2016 changes to the Federal Medicare programs which gutted almost one-third of the U.S. market. The current GenUltimate! competes directly with one of the largest worldwide platform manufacturers the venerable Johnson & Johnson (Lifescan Inc.). GenUltimate! (and the earlier GenStrip 50) were developed for use with the OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by over 3 million diabetes afflicted Americans and 5.8 million diabetics world-wide. GenUltimate! competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product, designed to meet new European Union standards is a much improved version. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the J&J legacy products but are dealing with escalating prices and lower insurance reimbursements. At the time of the introduction of GenStrip in March 2013, J&J controlled just under 30% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market.

Throughout 2012 in anticipation of the introduction of Genstrip, we evaluated our brand-name distribution model, a model that provided streams of revenue but extremely low profit margins, and over the course of the last 30 months we have phased out sales of those brand name products that had been a backbone of our distribution business. In addition the brand name products distribution business created a situation where we were selling products that competed directly with our GenUltimate! Phasing out these brand name products lowered our order intake but allowed us to become a manufacturer, in the nomenclature of both the U.S. FDA and the ISO group, operating at a much higher level in the greater market channel.

On November 1, 2011 we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC was a design company that specialized in product packaging design, medical products advertising design and graphic art. Ms. Binder subsequently joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with our contract manufacturers for GenUltimate!, making subtle changes to packaging design and more recently integrating the new FDA UDI product identification data system, among other responsibilities. She is also responsible for the package design for new diagnostic products the company is currently working on, including the upcoming GenSure!, GenChoice! and GenPrecis! products. Ms. Binder is also owner of GenstripDirect LLC and Full Circle Diabetes LLC, her own distribution companies, which she operates separately from her (Decision Diagnostics Corp. and Pharma Tech Solutions, Inc.) company related responsibilities.

We also intend to acquire additional private companies, or partner with small engineering companies that have developed technology requiring either regulatory approval, distribution expertise or both. We are moving quickly to achieve our goal of becoming a vertically integrated, full service value added provider of products and services to an ever-growing market. The at-home diabetes testing market continues to grow as diabetics continue to be diagnosed and treated. The market for diabetes testing products is already in the tens of billions of dollars continues to grow rapidly. We also intend to make additional capital investment later in 2017 in our Korean contract manufacturer and advanced development partner for the manufacture of GenPrecis.

The company's current proprietary product offering, cleared by the FDA for commercial distribution on November 30, 2012, is its newer version GenUltimate! blood glucose diagnostic test strip for at-home testing. Genstrip, the original product, is a product originally conceived by Shasta Technologies LLC, who proved incapable of attaining the necessary regulatory approvals after two attempts, 2009 and 2010/2011. In addition the original Shasta concept could not clear the FDA 510K process and had to undergo major design changes and a new 510K application that was eventually sponsored by this company. The original Shasta product was acquired by our Pharma Tech subsidiary on March 20, 2014, and fits into a diagnostic product niche, fitting nicely into the world-wide self-test (home test) market that has been growing at a 15% annual rate. Since GenUltimate! (and the soon to be GenChoice! product) is a rather unique product offering, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter) -- razor blade (diagnostic test strip) market, the Genstrip 510(k) application made for unusual challenges for the FDA and an educational challenge and opportunity for the company. In fact, the company finally (March 15, 2016) concluded its dealings with the FDA pre and post market review staff, an on-going process that was begun on a sour note by Shasta in October 2009. The company believes that future product offerings that will be regulated by the FDA will be a much smoother process, particularly since receipt of this directed landmark ruling by the U.S. FDA, covering our third party developed diagnostics (developed, in development and to be developed). Since the company plans additional similar products in the future for other diagnostic platforms, in fact a product announced still in the current reporting year, the Genstrip/GenUltimate! experience, however slow and unresponsive it was, has provided lessons and experience which is already being put to use.

Until our receipt of the landmark March 2016 ruling from the FDA, two years (and growing) was a standard development to market timeline for in-vitro diagnostic products similar to Genstrip / GenUltimate! We are confident that new products will enjoy a much speedier FDA review process. As a result of previous delays and failures by Shasta Technologies in completing its FDA approval application [510(k)] and then problems Shasta encountered in prosecuting its two original applications with FDA staff, the company changed its contractual responsibilities and obligations in June 2011 to include program management, regulatory process management, management of the manufacturing forecasting and distribution processes, and new products planning and development. Further (eventually fatal) on-going problems encountered by Shasta, which on their face proved irresolvable, presented the company with an opportunity. On March 20, 2014 our Pharma Tech Solutions, Inc. subsidiary acquired the intellectual property, the marks, and the GenStrip cleared 510(k). Subsequently we accomplished a rebranding of the original Genstrip product (GenUltimate!), built manufacturing protocols, improved the design of the product, implemented a robust Quality System throughout 2014 and 2015, and then developed the improved GenUltimate! product. GenUltimate! has become the only product of the original Genstrip line that will be packaged to conform with the FDA UDI standards, and was released as UDI compliant as of September 24, 2016. Manufacturing of Genstrip 50 ended and on-going sales will continue under the GenUltimate! brand, and will include the FDA UDI packaging.

In June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product, then about to enter the 510k regulatory review process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip,

while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA. Discussions with this retailer and other similarly situated retailers had been on a litigation induced hiatus since our litigation with Lifescan, Inc. began in earnest in late March 2013. Lifescan Inc., the diabetes testing division of Johnson & Johnson sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose was to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. The company believes there will be additional limitations as long as Johnson & Johnson spends large sums to discredit the company and its products. One such limitation was recently uncovered whereby Johnson & Johnson Lifescan effectively created an illegal embargo of the company's products by punishing their "Franchise" buyers with burdensome renewal contracts that barred these "franchisees" from buying our products or face the loss of rebate commissions. These rebates typically made up a considerable portion of the "franchisees" compensation thereby creating this illegal embargo of the company's alternative products. This practice by Johnson & Johnson Lifescan finally ended in late May 2017. Subsequently the company's efforts in these markets has improved greatly.

Through our settlements with Johnson & Johnson Lifescan we did achieve a hard-fought victory, particularly since Shasta had admitted (in February 2015) to patent infringements of all three J&J patents that were being adjudicated, in return for a cash settlement. During the remainder of 2016, we settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount, for lawsuits where the company was a defendant, a rarity in matters where the Plaintiff initiated the strike suit. J&J, as a part of the settlement, also granted the company licenses to three of J&J patents (one patent that J&J subsequently lost through final action by the US Supreme Court), the larger value gained from this 5-year legal battle. Johnson & Johnson Lifescan took the liberty of asking the court to make the settlement amount confidential, something a Plaintiff, on the losing end of a lawsuit, would want to do.

In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents. In March 2017, after a protracted battle with J&J where they tried to invalidate the company's lawsuit, the court in a major ruling agreed that the company will be allowed to move forward (a major victory so early in the suit) and will also be allowed to allege the Doctrine of Equivalents, a legal doctrine that would preclude J&J from twisting words through its pleadings and expert reports to escape justice. In April 2016 the company amended its original suit to include allegations under the Doctrine of Equivalents.

"The doctrine of equivalents is a legal rule in many (but not all) of the world's patent systems that allows a court to hold a party liable for patent infringement even though the infringing device or process does not fall within the literal scope of a patent claim, but nevertheless is equivalent to the claimed invention(s)."

The company's case for Patent Infringement is in a short termed but critical discovery phase, where briefs have been written, expert testimony taken, and the positions of the companies set. We feel that we retain the upper hand in this lawsuit. We make our penultimate filing on August 28, 2017. This filing will lead to an eventful Fall schedule and we believe will set the court clock for the prospects of a well earned settlement in early 2018.

In January 2016 the US Supreme Court ruled that the Doctrine of Laches, a defense used by many Defendants (including J&J Lifescan) in patent infringement suits could no longer be used. This ruling further deprived J&J of its most important defenses against the company's current patent infringement claims.

Currently the diabetes testing market is dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Our Genstrip's original introduction, even with the fits and starts, employed a business model different than those models employed by the major market players. Recent successes in the on-line marketplace has allowed the company to alter the market dynamics, lowering average price (which has occurred) or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations. Although this has been part of the company's plans in the recent past, the difficult litigation as well as the advent of the July 2013 and July 2016 changes to Medicare reimbursement (subsequently followed by private insurers) and the October 2016 reimbursement engineering, pharmacy business models are now blurred. Thus the company successfully added on-line sales to the major on-line Marketplaces to its business model.

The on-line sales Marketplaces have added greatly to the company's success and that of its products. However, over the last several months the number of sales groups advertising on the on-line Marketplaces grew to the point where the company had to add a "product detective" to oversee sales, in particular on Amazon's Marketplace. Many sellers were not buying product directly from the company, in fact "front run" product and began advertising, and using non-approved product images that nonetheless carried the company's copyrights, and then backordered shipments in order to acquire product that had already been sold to diabetics. This front-

running activity has placed great pressure on on-line Marketplace prices. To that end, the company has embarked on "cleaning up" the Amazon site, a large task, and sales for 3Q 2017 may or may not ultimately be impacted.

The company has also implemented a very successful "direct to diabetic" business model and has (independently or along with our distributors) executed on-line agreements with several of the largest retail chains, diabetic supply co-operatives, group purchasing organizations, as well as on-line mass merchandisers such as Amacon.com, Ebay, Walmart, Sears, Jet.com and approximately 950 other on-line cooperatives. The company considers this rapid adoption to be a huge success gained in a very short period of time.

In addition, sales may be impacted negatively due to recent marketing efforts by Johnson & Johnson's diabetic division Lifescan. Lifescan has made an effort to move their OneTouch Ultra market share to the Verio line of products. This includes extensive promotional efforts for the Verio meters, a supposed (threatened) withdrawal of support for Ultra products, and a decrease in the production, marketing, and availability of Ultra products. This was a successful strategy in Great Britain during 2Q 2017 and might be successful in the U.S. and Canada. However, given the spotty history of mass meter switchover programs, the company believes a significant number of users who "take the bait" and switch to the new Lifescan meter may be displeased with the cost of the new supplies. The company plans to implement educational promotions to educate the customer on the benefits of continued use of legacy Ultra meters.

The company in the past has also offered information technology solutions in several medical care market channels by providing physicians with information at the point of care. Our products, unlike those from many other medical information companies, make use of smart cell phones such as the Apple iPhone, the Palm Pre, the Google Droid and a wide selection of Microsoft Windows based smart phones and operate in either in a wireless or "wired" mode, which allow physicians to carry, access and update their patients' histories, also known as electronic medical records or EMR, medication data, and best care guidelines - *all at the point of care*, or from any other location the physician may be located. In addition, the company's products employ proprietary mathematical game theory features adapted by the company for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times. Since the advent of "Obamacare," promising products like our own struggled to gain market acceptance in a reimbursement challenged market. While we have kept up with the evolving regulatory changes, we do not foresee implementation of our products and networks in the near future.

In October 2014 we adopted a value added/private label business model to address the issues brought to our market by the radical reimbursement changes by the federal Medicare program. We also hired a market executive with over 40 years of experience to implement our new strategy. We have doubled down on this strategy and now employ not only the services of the aforementioned expert, but also additional of his partners and colleagues of his including the professional who put together the industry's "big box" pharmacy private label plan for diabetic test strips in 2006.

In March 2016 also retained a product source company called Retail Monster, to represent our products to large drug chains ("big box pharmacies"), large retailers, chain grocers and the like. Unfortunately the arrangement with Retail Monster did not succeed, primarily because a group of company shareholders and persons claiming to be shareholders poisoned our relationship Retail Monster. After these incursions by shareholders and persons claiming to be shareholders, our relationship with Retail Monster remained cordial, but nonetheless the two companies decided to end the engagement on December 31, 2016. Since August 1, 2017 the company has moved to re-engage Retail Monster.

The efforts being expended in the "big-box" arena are greatly aided by the company's recent success with the explosively growing on-line Marketplaces, many sponsored by the large retail pharmacies and retail stores. These Marketplaces are fast growing sister organizations to these retailers. The company's recent successes in the on-line Marketplaces has given the company a beachhead in this market as the uncertainty brought on by the J&J lawsuits has (finally) waned. In mid-March 2016 the largest US retailer agreed to raise the company's standing to the highest retail "rung" by offering a new supplier contract.

Oftentimes the largest pharmacy products retailers operate in non-colluding lock-step. Thus the company has been contacted by several chain drug and department store retailers to repackage our products for exclusive sale to these retailers. So, for example, the company has a Trademark on the trade name Alltara, a trade name fiorst explored for our GenUltimate! product. The company plans to package our GenUltimate! and (eventually) GenChoice! products under the trade names Alltara Ultimate and Alltara Choice and offer these (trade named) products on an exclusive basis to the nation's largest drug store chain. Recently, the second largest drug chain has asked for similar treatment. The company is in the process of securing a trademark for the trade name Advanc which will be offered to another large retail chain as an exclusive product(s). By doing these repackaging projects, the company believes we will have our products on large retailer store shelves in an accelerated fashion.

During the 2Q 2017 the company has signed agreements with two distribution outlets, one in New York -- Altro Pharmaceuticals and one in Florida -- Virtue Rx, for the sale of our GenUltimate! and GenChoice! products. In addition, the company

has come to agreement with a large shareholder who is in the process of setting up media spots for the direct sale of product to diabetics in the New York and Cleveland, OH metro areas. Additional cities will be added throughout the remainder of 2017. The company is excited about this particular opportunity because the sale will be direct to diabetic through TV infomercial and fulfillment centers. The diabetic buyer will not be required to shop for the product like they do currently on the company's hugely successful Amazon.com portals.

In May 2017 the company was approached by an independent third party company whereby this company made an informal offer to acquire all of the capital stock, cash, assets, and intellectual properties of the company, as well as assume all liabilities including the debt of the company and its subsidiaries, and to assume the disposition of the company's lawsuit against Johnson & Johnson and its subsidiaries Lifescan Scotland and Lifescan, Inc. The company responded to this informal offer by requesting that the proposed suitor formalize the offer in a more detailed Term Sheet or Letter of Offer. The suitor then came back with a confidential formal offer to which the company's Board of Directors through the Principal Executive Officer responded in early August 2017, neither accepting nor rejecting the offer and asking for several areas of clarification, and later rejecting one of the proposed suitor's requests, this for a "stand still" agreement. The company, through the Principal Executive Officer has remained in direct contact with the proposed suitor.

Since March 2015 when we first we acquired special intellectual property and specialty manufacturing equipment which will shall serve our business interests now and into the future. We have increasingly turned to Alpha Capital Anstalt ("Alpha"), Navesink Device Initiatives and Licgo Partners, and most recently Sovereign Partners LLC and Manhattan Global Ventures (the Bolivian partner) whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C stock units and/or Preferred D stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. In 1Q, 2Q and 4Q 2016 we completed additional financing transactions with both Alpha and Licgo. In 2Q 2017 we accepted the Subscription of Manhattan Global Ventures for a #$3.25 million investment, and in the current quarter we accepted the subscriptions of Sovereign Partners LLC for an investment of up to $2.5 million with a $450,000 overallotment. These most recent investments carry with them three year "lock up" terms, precluding share conversions for three years from the time of the offering. Our most recent transactions with Alpha also financed an inventory credit line for the company so that we can meet the requirements of the largest retailers and maintain at least $400,000 in stock on hand at any time. In August 2017 Alpha added to this credit line with an additional $350,000 investment. Our relationships with our financiers are amicable and strong. In addition to the above, Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop our new GenChoice! product, and will finance (shortly) specialty manufacturing equipment for our new GenChoice! product, meters and test strips. These additional investments will raise the manufacturing capacity of our partner, The Bio Coo., Ltd to just over 1 million vials of test strips per month.

In the Fall of 2014 the company announced its Discretion cloud wireless glucose monitoring product concepts, which will be manufactured for the company according to spec by its Korean contract manufacturer. In April 2015 the company entered into discussions with HMD Biomedical, Inc. in Taiwan for the importing of HMD's FDA cleared "Cloudia," product as a placeholder until the company's Discretion Messenger product for children would be ready. We ended our discussions with HMD Biomedical in October 2016, after determining that the "Cloudia" product was not robustly developed enough for North American markets and to further develop this product would require another 510(k) approval from the U.S. FDA which we did not wish to undertake. And given the number of products we are currently in the process of developing, we also plan to phase out our Discretion Companion (young persons') meter and strip product. Instead we plan to add the wireless features to our GenPrecis! Precise meter, offering a solution to young people (Type 1 diabetics) with small hands and fingers as well as to the Type 2 (adult onset) diabetic base of users.

To that end, the company's exclusive agent in Korea was contacted by the Korean government, who apparently was willing to finance the Discretion systems initiative through its advanced development, clinical trials and FDA prosecution. Different than, for example, an NIH grant, this grant from the Korean government, if was accepted by the company, would include investment in the company's contract manufacturer as well. We have chosen to present the GenPrecis! product to the Korean government for this R&D funding, but with our recent capital financings, if the Korean government decides not to fund GenPrecis! systems, we are well enough financed to fund the development ourselves. In addition, the company has completed a further development of it's MD@Hand product, allowing diabetic users of the company's GenPrecis! products to monitor and track their diabetes treatment and testing on their smart cell phones, laptop computers, and computer pads.

The company entered into two international agreements in the latter part of 2016. The first agreement, executed through the company's exclusive Korean agent, allows for delivery of the GenUltimate! product in quantity to the Korean market. As of this writing, the Korean partners have ordered and paid for over 95,000 pieces (units) of GenUltimate! Another almost 17,000 pieces (units) are on order for late August 2017. The company's second international agreement is through a South American financier who has businesses in Bolivia and Spain. This financier has also secured approval to market GenUltimate! throughout Central and South America through a powerful trade organization, allowing for sale of GenUltimate! Strips and meters without any additional political or governmental approvals. This group has placed a single two-year (term) order for approximately $17 million in GenUltimate! product, GenUltimate! meters and the company's new (2017) Firefly! Lancets. Almost 11,000 pieces (units) of GenUltimate!, 3,000 GenUltimate! meters and

cases of lancets have been delivered to Bolivia. In addition, the South America financier has funded the company's regulatory applications (through a Spanish pharmaceutical company) with the EU, to gain "CE" marking for its GenUltimate! and GenSure! products (and later in 2017 the company's GenChoice! and GenPrecis! Products) in return for the Spanish distribution rights to these two products. And lastly, the South American financier that he wished to subscribe to a $3.25 million to $5.00 million capital investment in the company. As of this writing the company has not concluded this capital investment, at its choice, but has received a signed and dated a Subscription Agreement for this upcoming investment from the financier. On June 30, 2017 the company accepted the Subscription Agreement for the company's Preferred D units. Funding of the Subscription is expected by August 20, 2017. This Subscription Agreement is also described in the company's 2Q 2017 Financials. Among the many terms in this investment, the South American financier will not be able to convert and sell any securities that underlie the investment vehicle for 36 months from the time of the investment.

We have received multiple inquiries from companies interested in perhaps collaborating with the company for the implementation of its cell phone centric technologies MD@Hand and MD@Work. However, the market available for products similar to MD@Hand and MD@Work has changed since its introduction in 2009. The legal challenges to the new health care law and the federal government's inability to enact regulations have altered the landscape, again. We remain in discussions with multiple concerns for the marketing of our MD@ products, and any agreement we may enter will require us to provide contract software programming, providing a new source of revenue for the company. In addition to any proposed partnerships, we continue to discuss alternative propositions with other interested companies ranging from clinical laboratories, service organizations owned or aligned with medical health insurers, a medical content provider and legacy healthcare systems companies. There remains sustained interest in our MD@ technology. We may or may not entertain additional proposed partnerships for our implementation of the cell phone centric technologies, which has been hindered, as has the overall market, by the slow implementation of regulations, protocols and data formats by the Federal government, as well as a change in previously announced Federal government monetary incentives.

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip ("Genstrip"). The Genstrip product was developed to compete against the market leader in the then $6.5 billion at home testing market. Shasta was in default of this 2010 Agreement within 90 days of its initiation. Penalties under that agreement and monies owed totaled in excess of $2 million in "delay" penalties, which they were unable to pay. In April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. Shasta defaulted under this agreement as well. On March 20, 2014 we acquired the GenStrip intellectual property, its marks and the cleared 510(k). Shasta defaulted on this agreement as well. In addition Shasta breached or defaulted on two insurance settlement agreements, owing to the aforementioned J&J litigation. And finally, Shasta confessed to patent infringement of J&J's three patents.

On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenUltimate! test strip. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product.

In August 2016 the company settled an insurance matter with Gotham Insurance, an IP Defense insurer, and Shasta covering legal fees associated with the 2011 and 2012 lawsuits brought by Lifescan, Inc. This settlement included a stipulation by Shasta to cease contacting and sharing confidential documents with persons who identified themselves as DECN shareholders. Several of these persons who contacted Shasta also contacted the aforementioned Retail Monster management. The stipulation gained in insurance settlement with Shasta does not preclude the company from pursuing Shasta, its principals and these "shareholders" in its omnibus lawsuit brought against Shasta et al. in 2014. The company plans to amend its 2014 complaint to name additional Defendants including those persons who owned stock in the company who may have traded stock in the market based on information and documents provided by Shasta.

We currently employ eight professionals at or locally managed through our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We are hiring additional professionals in the U.S. and Korea. We have also maintained a Quality Assurance office in York, PA, which we closed on June 23, 2017, and our exclusive agent in Seoul, Korea maintains another QA office as a means to fulfill our quality commitments to the FDA for product manufactured under our oversight in Korea. We also maintain a large portion of a public warehouse in Miami, FL where we pay its proprietor to store, maintain inventory and ship product to our customers. This proprietor also manages the company's customs broker who works with the company for our importing and exporting of product worldwide. Our telephone number is (805) 446-1973 and our website addresses are www.decisiondiagnostics.com and www.pharmatechsolutionsinc.com and www.genultimate.com. Additional web sites will be added for our GenChoice! product (site in development) and our GenPrecis! Product.

As a part of the company's strategic plans, we have applied (to register) for seven Trademarks with the USPTO. The company's Genstrip product is a registered Trademark of Shasta Technologies LLC. Our applications were filed with the USPTO in 1Q and 2Q 2015 3Q 2016 and 2Q 2017. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry. As December 31, 2016 the company has received registration confirmation from the USPTO for the following Marks:

"Alltara!"
"GenUltimate!"
"GenSure!"
"GenChoice!"
"GenAccord!"
"GenCambre!"
"Firefly!"

In early May 2017 the company filed for a mark on its GenPrecis! Product.

Beginning in the 4th Quarter 2015 and through 2nd Quarter 2016 the company suffered severe inventory shortage of the Genstrip 50 product at various times, owing to the timing of the various settlements with Johnson & Johnson by Shasta and a contract manufacturer, Conductive Technologies, Inc. For some period of time Conductive was unable, due to their settlement with Johnson & Johnson, to ship to the company any quantities of the Genstrip 50 product. This problem began to clear up in late May 2016, and with the advent of adding the GenUltimate! product from Korea, shortages have been alleviated. The company is currently not buying any product from its Pennsylvania contract manufacturer, and is undecided whether we will sign a new contract original scheduled for implementation on January2, 2018. The company's capacity for GenUltimate! production is now 625,000 packages per month (50 count and 100 count packages) and manufactured in Korea, for the new GenSure! product 250,000 packages per month (25 count and 50 count packages) to be manufactured in Korea, and the new GenChoice! product 500,000 packages per month (50 count and 100 count packages) to be manufactured in Korea. Recently, a mega- retailer has requested the company keep minimum inventories of finished product of 350,000 units on hand. We expect other retailers to make similar requests.

On May 5, 2017 the company was contacted by a worldwide private label manufacturer and distributor for the purposes of worldwide distribution of our products under their brand(s). We are in discussions with this entity currently. This company has headquarters in the U.S. (Midwest) and France.

The company's stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company's shares are DTC eligible. On May 12, 2015 the company made an application for a tier change to the OTCQX (common) tier. When the company's common stock fell in price beneath the $.10 threshold, and when our sponsoring broker shuttered his operation, our application went into hiatus. Subsequently, we have been in contact with OTCMarkets and we plan to revive our application, and to that end we have filed for uplist on OTCMarkets as an Alternative Filer. This uplist will move the company's stock listing to the OTCQB level. The company has received a tentative approval for this uplist pending an audit of the company's 2016 balance sheet. In July 2016 the company contacted several auditing firms and has received two engagement letters for our Board's review. Most recently we contacted our former auditor (dating to 2011) and with whom we shared an excellent working relationship. This firm has settled its differences with the U.S. PCAOB owing to a rogue accounting partner who remains barred. We expect to receive their engagement letter and if forthcoming, the Board of Directors would approve their engagement.

In September 2016 we were contacted by a shell company, Appyea, Inc. to complete an M&A transaction that would have led to the company's merger with that company under the terms of 96.5% / 3.5% (about standard for these type of trasactions), terms that were offered by Appyea, Inc.. A confidential Preliminary Agreement was executed and then breached by Appyea, Inc. when Appyea decided to raise capital and dilute their stock by approximately 50% during a well defined "stand still" period, using the rumors of a merger to propel their stock. The company has received several offers from Appyea, Inc. as a break-up consideration, which we have found unacceptable. The company has forwarded our final demand of settlement.

Business activities throughout the next twelve months:

The company's business on a day-to-day basis includes the distribution of our GenUltimate! products, (50 count and 100 count versions). Also within 90 days of this writing, the company will introduce its GenSure! product which has recently concluded its clinical analyses. GenSure will be sold in certain International markets. In the next 120 days the company will have concluded the clinical

analyses and filed for 510K clearance for its GenChoice! product (50 count and 100 count versions). The GenChoice! product will be sold worldwide.

Beginning in November 2009, we introduced our cell-phone centric medical IT products that offer solutions in medical care and management by providing physicians with information at the point of care. Unlike other medical information systems using standard computer terminals or even palm-sized computers (PDA's), our software applications operate on a series of late generation smart e-cell phones including the Apple iPhone, the Palm Pre, the Google Droid, several makes of RIM's Blackberry and many versions of the Microsoft Windows smart phones. Our products allow physicians to access and update their patients' histories, medication data, and best care guidelines - *all at the point of care*. The company's Electronic Medical Records software is believed to be the first EMR application running on any palm sized mobile device. Recently we ported our software to run on a series of pad computers such as Apple iPad and the 'Droid powered pads. We eagerly await the new version of the national health plan, which might finally create markets for our products.

Our 12-month business objectives include:

1. The practice of specializing in the distribution of GenUltimate! and GenSure! products, and then completion of the GenChoice! product. We also intend to add several brand-name medical diagnostic and medical disposable products (lancets through our Firefly! Product, as well as several lines of insulin syringes and pen needles, all associated with the on-going care of diabetes-inflicted patients, and the world-wide distribution of our proprietary diagnostic product GenUltimate! product.
2. Combining our wholesale and retail diagnostics distribution with the major successes we have had in the on-line retail markets, and adding legacy retail organizations (already some legacy retailers of note).
3. Continue to implement the plans provided by our agent MWK LLC, and secure big-box pharmacy chains, chain grocers and nationwide retailers.

Recent Business Milestones

In 2016-2017 the company has accomplished the following milestones.

1. We completed the design and manufacture of GenUltimate! glucose test strips for the U.S. and international markets.
2. We began advanced development of two new test strip products, our GenSure! and GenChoice! test strips. GenSure! is slated for a July 2017 product launch, GenChoice!, which requires FDA clearance, is slated to be ready for market in late 2017 if the company decides not to launch the GenChoice! product outside the U.S. initially.
3. We settled our lawsuit with the divisions of Johnson & Johnson. Although settlements of litigation typically have no winners, in this case the company benefitted through the receipt of a cash settlement payment as well as licenses to pursue Johnson & Johnson's test strip patents.
4. We brought suit against Johnson & Johnson and several divisions for manufacturing products that infringe on our patents. Recently we won a major early battle in this suit where the trial judge granted us the opportunity to argue the Doctrine of Equivalents, an important concession in this case given J&J's penchant for the twisting of words and drawing lines through random dots. This suit began its prosecution phase on March 15, 2017 with the trial judge's early ruling. This suit is now well in progress.
5. Our Discretion Messenger wireless glucose monitoring device and test strips has received an offer of a grant from the Korean government for its advanced development, clinical trials and FDA prosecution. Discretion Messenger is a product designed for diabetic children and their parents and caregivers. The company's grant was delayed by political issues that arose with the South Korean government.
6. The company initiated a marketing program to the on-line Marketplaces sponsored by pharmacy chain, department store and grocery store retailers, as well as mass merchandisers, and including the largest retailers. This program has so been the most successful endeavor since our inception.

Financing Requirements

At June 30, 2017, we had cash of $749,894 and negative working capital of $275,825. We anticipate that we will require $67 million in trade debt financing to finance our expected sales of GenUltimate!, GenSure! GenChoice!and GenPrecis!. as the company enters a new products driven growth phase. Debt financing is institutional debt where the debtor shares risk for the company's inventory

purchases, receivables and products in transit. We are seeking traditional commercial credit and what we are seeking should not be confused or tortured into claims that the company is seeking non-traditional microcap company gimmick financing such as Equity Lines of Credit or similarly toxic transactions, which are neither purchases of Equity nor a Credit Facility.

In March 2012 we renewed an agreement with Alpha Credit Resources ("ACR") for a third time in order to obtain this debt same financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our pervious line. This credit line was for $12.5 million, but with the velocity of our product sales, could yield over $250 million in annually available credit. Other than Alpha's offer of this credit line, which turned out to be a great work of fiction, the company had not done any work with Alpha or borrowed any funds dating back to September 2011. Subsequently we learned that ACR's parent, Platinum Credit became the subject of several Federal criminal investigations. ACR has not. ACR is not a part of the Platinum Credit liquidations filed in September 2016. Nonetheless, despite not having endured any prior business relationship with Platinum Credit, the company immediately froze all of its securities held by ACR. In addition ACR had not been granted any requests for any conversion or sale transactions since December 2014, nor have they requested any. As a part of this liquidation, the company is now seeking return of most of the securities granted to ACR from 2007 through January 2015.

We will from time to time continue to seek a combination of equity and long-term debt financing as well as other traditional cash flow and asset backed financing to meet our financing needs and to reduce our overall cost of capital. Additionally, in order to accelerate our growth rate and to finance general corporate activities, we may supplement our existing sources of funds with financing arrangements at the operating system level or through additional short-term borrowings. In these times, we turn to existing shareholders with the wherewithal and the knowledge to complete the financings. Alpha Capital Anstalt and Navesink/Licgo/Sovereign Partners have been used throughout our business plan. As a further capital resource, we may sell or lease certain rights or assets from our portfolio as appropriate opportunities become available. However, there can be no assurance that we will be able to obtain any additional financing, on acceptable terms or at all.

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our original Genstrip product required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, Genstrip required medical patient trials and competes directly with a major platform manufacturer. We insure against any claims made against the company for our Genstrip product.

Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers. It is not uncommon in our industry to find that a litigant has filed claims in multiple jurisdictions involving the same transaction or a single transaction. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of December 31, 2016, our accrual was $240,000 and $245,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered potentially material to us.

We were in litigation with Lifescan Inc. a subsidiary of the Fortune 25 Johnson & Johnson, beginning in September 2011. Lifescan had maintained throughout that our Genstrip product infringed on three of their patents. One of these patents has become the subject of peripheral litigation activities, and two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). In January 2016 the Court of Appeals for the Federal Circuit ruled in its Mandate that this one foundational patent and the claims made by the assignee Lifescan, Inc. was struck (killed) due to obviousness (a clever wording meant to obscure a connection between the Lifescan, Inc. invention and earlier generation technologies dating back to the late 1970s). Throughout this Appeal process, and a litigation process waged through the USPTO, the company prevailed. Recently, as a result of certain claims and allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General intervened

against Lifescan Inc. in the Federal Circuit court and was of great assistance in getting the Lifescan, Inc. patent revoked. Nonetheless the seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell our products in large quantities to large entities ("big box stores") and greatly extended the court processes.

In the Spring of 2013, fearing the impact of the Genstrip product in an open market, Lifescan took it upon themselves to violate a court protective order and prepared and sent out thirty page certified (veiled threat) letters to customers of the company and the customers of the company's customers, making it clear to these entities that should they do business with the company, or buy Genstrip product from others doing business with the company, they could or would be added as defendants to the patent infringement suit. Most independent pharmacies in the U.S. sell less than a case (24 boxes) of a single brand of glucose test strips monthly. It is easy to ascertain that an independent pharmacy would choose not to "poke the bear" and risk a several hundred thousand dollar defense, rather than halting sales of Genstrip. Some large retailers were visited or called by Lifescan management and provided with face to face veiled threats. Lifescan even calculated that by breaching the protective order, the sanctions they would be assessed would amount to far less than the business loss they would otherwise suffer. Slowly however, the litigation environment enjoyed by Lifescan changed in our favor.

In December 2014 counsel for Lifescan wrote a letter to the trial judge who was hearing all three patent matters. This letter outlined a series of issues involving Lifescan's lead damages "expert" during litigation proceedings. Lifescan's expert claimed educational and qualification credentials that were not true at the time of the "expert" testimony, and are not true even today. This expert also assisted Lifescan's counsel in at least one other case, and other companies' counsels in unrelated cases. Testimony from this expert, in each instance, allowed the Plaintiffs in these cases to secure court rulings to the detriment of the Defendants, one of these Defendants being the company. In the company's case this expert was used twice and assisted Lifescan to receive preferential treatment from the court for setting of a litigation bond to cover potential damages, wherein the "expert" through testimony limited the scope and calculation of damages in the setting of the damages protection afforded by the litigation bond and the damages resulting from Lifescan's violation of the court protective order. Lifescan's letter admonition came over a year after their successful use of this "expert."

In March 2016 the company filed suit in the Federal District Court of Nevada against Lifescan, Inc., Lifescan Scotland, Ltd. and Johnson & Johnson, citing infringement of two patents owned by the company. After an exchange of demand letters and posturing by the Defendants, including Defendant's Motion to Dismiss, the company prevailed in an important early determination by the trial judge. At a hearing in March 2017 the Federal judge denied Lifescan's Motion to Dismiss, granted the company's request to allege the Doctrine of Equivalents and set dates beginning in early April 2017 and ending in early November 2017 that could set the stage for a ruling. Sometime after September 18, 2017 the company expects to amend its suit a second time and name other "infringers" as well as adding additional counts to the suit. All of these supplemental "infringers" have been contacted and put on notice. Federal rules for patent infringement suits have changed, and these suits are now adjudicated over an 18-24 month period. The trial judge's ruling in mid-March seems to foot with this schedule. In addition, if the schedule set by the judge does not end the litigation, there are five scheduled Mediations in front of a Federal Judge Magistrate pushing the process along. The company amended its suit in April 2017, alleging patent infringement on behalf of the J&J entities under the Doctrine of Equivalents. The J&J entities answered the amended complaint later in April, and the (next step) expert testimony has begun. This part of the litigation process will end on September 18, 2017, after Lifescan is allowed to file its final rebuttal. From then until early November the trial judge will make his ruling. The company is extremely optimistic of the expected outcome.

On May 20, 2016 the company settled all of Lifescan's patent infringement claims as well as the company's Anti-trust and false advertising counter-claims against Lifescan, Inc. and Johnson & Johnson. Neither side in these litigations was a clear winner, but Lifescan did pay the company's settlement demand, rare for a Plaintiff to pay a Defendant. Lifescan also granted us a license to three of their patents which also offered future value to the company. The company's products were artificially denied a market for almost 3 years, but on the other hand, the company did receive settlement monies and other compensation from Lifescan. The company also planted a seed during the settlement with the court whereby Lifescan was notified that they would be held liable for future anti-trust violations through their continued illegal embargo of the company's products with their "franchise" customers, primarily big-box pharmacy chains. One year later Lifescan ended this illegal embargo paving the way (finally) for the company's free enterprise. Our disputes with J&J/Lifescan were complex cases, and given the complexity, J&J/Lifescan was able to employ foot-dragging strategies, the engagement of experts who lied about their credentials, the writing of 1500 letters threatening most of the higher volume independent pharmacies with separate litigation if any of these pharmacies bought the company's products, and finally an illegal embargo implemented through contract renewals with their "franchise" customers. Although the settlement with J&J/Lifescan was confidential, the company did prevail, a set of noteworthy achievements. The settlement with J&J/Lifescan included licenses to the Lifescan Inc. patents which were of great value to the company in the overall settlement, as will be seen throughout the remainder of 2017 and into 2018.

A. Date and State (or Jurisdiction) of Incorporation:

INCORPORATED IN THE STATE OF NEVADA ON MARCH 2, 2001 AS ATR SEARCH CORPORATION

B. the issuer's primary and secondary SIC Codes;

5122, 7371

C. the issuer's fiscal year end date;

DECEMBER 31

D. principal products or services, and their markets;

GenUltimate! Test Strips for use with Johnson & Johnson Lifescan glucometer, and GenSure! and GenChoice! glucose test strips. GrnPrecis! System (meter and test strips). MD@Hand medical communication and EMR software for use with smart cell phones.

7) Describe the Issuer's Facilities

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is $2,170 per month on a month-to-month basis. Our Pharma Tech subsidiary has maintained a facility for quality assurance and control of its FDA QSR at 750 Borom Road, York, PA through June 23, 2017, and another QA office is maintained by its exclusive agent in Seoul, Korea also for FDA QSR purposes. In addition the company takes the majority of the space in a public warehouse in Miami, FL where the proprietor of this warehouse manages, with company oversight, the importing, exporting, shipping, receiving and customs brokerage activities.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Our executive officers, directors, and key employees are:

Name	Age	Position
Keith Berman	63	Chief Financial Officer and Director
Robert Jagunich	70	Director

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. The company maintains two independent (outside) directors, who would become the Board's audit committee as we uplist along the OTCMarkets tiers. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

Keith Berman has served as President, Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. For over the past 38 years, Mr. Berman has been involved in the development of and marketing of medical products, particularly medical devices and in-vitro diagnostics. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director or Medicius, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., later Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

Robert Jagunich has served as a Director of the Company since January of 2003. Mr. Jagunich has 29 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

Mr. Berman, officer and director, works full-time for the company. Mr. Jagunich attends meetings of the board of directors when held and provides 20% and 25% respectively of their business time in professional capacities to the Company.

William Lyons, former director, resigned from the company's Board in July 2017. His replacement has been identified with an expected announcement in early September.

The following table sets forth information the remuneration of our Principal Executive officer for year ended December 31, 2016, and for the year ended December 31, 2015 through the current period inclusive:

Summary Compensation Table

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Keith Berman,	2015	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
CFO and PEO	2016	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
	2017	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2014 and 2015 and through September 30, 2016, Mr. Berman has received no cash compensation. Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock and stock option awards as his compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

Name of Beneficial Owner, Officer or Director	Number of Shares	Percent of Outstanding Shares of Common Stock*
Keith Berman, Chief Financial Officer and Director	480,103	0.0532%
Robert Jagunich, Director	929,301	1.093%
Directors and Officers as a Group	1,409,404	1.530%
Barbara Asbell 7061 Los Coyotes Camarillo, CA 93012	1,162,590	1.263%
Directors, Officers and Beneficial Owners as a Group	2,571,994	2.793%

* Category percentages vary from totals due to rounding. Share totals are correct.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Nevada Legal Counsel
Name: Thomas C. Cook
Firm: Law Offices of Thomas C. Cook, LTD.
Address 1: 1980 Festival Plaza Drive, Ste. 530
Address 2: Las Vegas, NV 89135
Phone: (702) 524-9151
Email: tccesq@aol.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

CERTIFICATION

I, Keith Berman, certify that;

(1) I have reviewed this disclosure statement and Quarterly Periodic Reports for the periods ended June 30, 2017 and June 30, 2016;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) revaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2017

/s/Keith Berman
Keith Berman
Principal Executive Officer and a Director
(Principal Financial Officer)

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Keith Berman, the Principal Executive Officer of Decision Diagnostics Corp., and Principal Financial Officer of Decision Diagnostics Corp.,., hereby certifies, that, to his knowledge, the Quarterly Periodic Report of Decision Diagnostics Corp. for the periods ended June 30, 2017, and June 30, 2016, fully complies with the requirements of this Disclosure Statement and of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report and this disclosure fairly presents in all material respects the financial condition and results of operations of Decision Diagnostics Corp. and its subsidiaries.

Date: August 14, 2017

/s/Keith Berman
Keith Berman
Principal Executive Officer and
Principal Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Decision Diagnostics Corp. and will be retained by Decision Diagnostics Corp. and furnished to any regulatory body or OTC Markets, Inc. or their staff upon request.